Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer

Journal of Immunotherapy

Volumn 37, Issue 2, 2014, Pages 105-114

  Nishida, Sumiyuki ^a,b   Koido, Shigeo ^f   Takeda, Yutaka ^a   Homma, Sadamu ^g   Komita, Hideo ^f   Takahara, Akitaka ^f   Morita, Satoshi ⁱ   Ito, Toshinori ^a   Morimoto, Soyoko ^b   Hara, Kazuma ^c   Tsuboi, Akihiro ^a   Oka, Yoshihiro ^b,e   Yanagisawa, Satoru ^h   Toyama, Yoichi ⁱ   Ikegami, Masahiro ^h   Kitagawa, Toru ^a   Eguchi, Hidetoshi ^a   Wada, Hiroshi ^a   Nagano, Hiroaki ^a   Nakata, Jun ^b   Nakae, Yoshiki ^b   Hosen, Naoki ^c   Oji, Yusuke ^a   Tanaka, Toshio ^d,e   Kawase, Ichiro ^a   Kumanogoh, Atsushi ^a,e   Sakamoto, Junichi ^j   Doki, Yuichiro ^a   Mori, Masaki ^a   Ohkusa, Toshifumi ^f   Tajiri, Hisao ^f   Sugiyama, Haruo ^c   more..

^a Department of Cancer Immunotherapy ^*  (Japan)

^b Allergy and Rheumatic Diseases   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f Division of Gastroenterology and Hepatology   (Japan)

^g Institute of DNA Medicine   (Japan)

^h JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^j NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

cancer immunotherapy; gemcitabine; pancreatic cancer; Wilms tumor gene (WT1); WT1 peptide vaccine

Indexed keywords

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADULT; AGED; CANCER VACCINES; CELLS, CULTURED; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; HLA-A24 ANTIGEN; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOLOGIC MEMORY; MALE; MANNITOL; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OLEIC ACIDS; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR SUPPRESSOR PROTEINS; VACCINES, SUBUNIT;

EID: 84894412309     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000020     Document Type: Article

References (42)

1. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7: 163-172.
2. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
3. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
4. Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet. 2009;373:673-683.
5. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480-489.
6. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
7. Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother. 2009;58:317-324.
8. Nowak AK, Lake RA, Robinson BWS. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev. 2006;58:975-990.
9. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59-73.
10. Ramakrishnan R, Assudani D, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest. 2010;120:1111-1124.
11. Takahara A, Koido S, Ito M, et al. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunol Immunother. 2011;60:1289-1297.
12. Huff V. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nature Rev Cancer. 2011;11:111-121.
13. Sugiyama H. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010;40:377-387.
14. Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms' tumor gene WT1 product in patients with hematopoietic malignancies. Blood. 2002;99:3272-3279.
15. Gaiger A, Carter L, Greinix H, et al. WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res. 2001; 7:761s-765s.
16. Oji Y, Kitamura Y, Kamino E, et al. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. Int J Cancer. 2009;125:381-387.
17. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic Tlymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics. 2000; 51:99-107.
18. Rezvani K, Brenchley JM, Price DA, et al. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res. 2005;11:8799-8807.
19. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA. 2004;101:13885-13890.
20. Morita S, Oka Y, Tsuboi A, et al. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol. 2006;36:231-236.
21. Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg. 2008;108:963-971.
22. Miyatake T, Ueda Y, Morimoto A, et al. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial. J Cancer Res Clin Oncol. 2013;139:457-463.
23. Tsuboi A, Oka Y, Kyo T, et al. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia. 2012;26:1410-1413.
24. Hashii Y, Sato-Miyashita E, Matsumura R, et al. WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission. Leukemia. 2012; 26:530-532.
25. Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113:6541-6548.
26. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111:236-242.
27. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
28. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 2004;5:655-663.
29. Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 2004;164:190-194.
30. Okada S, Ueno H, Okusaka T, et al. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol. 2001;31:7-12.
31. Gaiger A, Reese V, Disis ML, et al. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96:1480-1489.
32. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198-2203.
33. Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013; 31:1640-1648.
34. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
35. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013;31:23-29.
36. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother. 2011;60:433-442.
37. Weden S, Klemp M, Gladhaug IP, et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer. 2011;128:1120-1128.
38. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumorspecific CD8 T cells. J Immunol. 2003;170:4905-4913.
39. Nowak AK, Robinson BWS, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 2002;62:2353-2358.
40. Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11:6713-6721.
41. Rettig L, Seidenberg S, Parvanova I, et al. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer. 2010;129:832-838.
42. Pospori C, Xue SA, Holler A, et al. Specificity for the tumorassociated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. Blood. 2011;117:6813-6824.